A Phase II, Single-Arm Study of RAD001 (Everolimus), Letrozole, and Metformin in Patients With Advanced or Recurrent Endometrial Carcinoma
Status: Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 18 Oct 2019
Price : $35 *
At a glance
- Drugs Everolimus (Primary) ; Letrozole (Primary) ; Metformin (Primary)
- Indications Adenocarcinoma; Carcinoma; Endometrial cancer
- Focus Therapeutic Use
- 18 Oct 2019 Results assessing efficacy of everolimus, letrozole, and metformin in women with advanced or recurrent endometrial cancer published in the Clinical Cancer Research
- 09 Mar 2018 Planned End Date changed from 1 Oct 2018 to 1 Oct 2020.
- 09 Mar 2018 Planned primary completion date changed from 1 Oct 2018 to 1 Oct 2019.